In a Feb. 5 meeting with retail pharmacy CEOs, HHS Secretary Xavier Becerra stressed that patients should not be paying the full list price or high copays for Pfizer’s Paxlovid drug.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
